Hemostemix Announces its AI Strategy

Calgary, Alberta – August 19, 2025 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom Lawrence, Chief Commercialization Officer, Hemostemix, who completed executive education in Artificial Intelligence and Healthcare at the Massachusetts Institute of Technology (MIT), will present the Company’s phased approach to embedding AI across its patient engagement, clinical research and corporate operations.
“This webinar will showcase how we are applying artificial intelligence to transform every aspect of Hemostemix into the world’s first AI-driven autologous stem cell therapy company treating pain associated with no-option patients who can be treated under Florida’s SB1768, stated Thomas Smeenk, CEO.
“We know the future of regenerative medicine is physician-based AI-enabled workflows said Croom Lawrence, CCO. AI-based workflows generate a better patient experience, generates better recruitment, faster trials, best in class analytics, stronger patient outcomes, and more efficient patient care, Lawrence said.”
Patient Care Innovations
HIPAA-Compliant Precision Medicine Diagnostics – The platform unifies patient records, medications, co-morbidities, genetics, gut microbiome, and lifestyle data (exercise, diet, consumption patterns) into a single AI-powered analysis. This helps physicians see the patient’s full health journey while showing patients how lifestyle choices impact outcomes.
Accurist AI for Early Cognitive Decline – Leveraging mild cognitive impairment (MCI) screening, Hemostemix sets baseline assessments to monitor subtle memory changes before and after VesCell™ (ACP-01) treatment. Get yours today (clawrence@hemostemix.com)
AI-Powered Patient Engagement – Around-the-clock personalized chatbot support improves access and satisfaction while securely guiding patients through treatment, recovery, and lifestyle adjustments.
Patient Decision Support Tools – AI-driven insights assist physicians and healthcare coaches in tailoring plans that help patients sustain healthier habits post VesCell™ therapy.
Clinical & Scientific Advancement
Accelerated Research with AI – Under physician and research oversight, AI tools analyze patient data to predict treatment responses and refine VesCell™ (ACP-01) trial design.
Predictive Analytics for VesCell™ Outcomes – Focused to the patient, the therapy success rate will be modelled based co-morbidities, lifestyle patterns, and epigenetic markers.
AI for Trial Matching – Intelligent agents streamline recruitment by rapidly screening patient profiles against trial criteria, accelerating enrolment and onboarding.
Operational Efficiency
Automated Administrative Workflows – HubSpot-integrated AI agents manage scheduling, billing, and follow-ups, reducing overhead by up to 20%.
AI-Optimized Resource Allocation – Dynamically adjusts staffing, production, and supply chains in line with forward-sold therapy demand – Therapy Convertible Debenture – sales cycles.
Unified Data Ecosystem – A secure cloud-based system connects clinical trial data, and outcome metrics, ensuring seamless HIPAA-compliant access.
Proactive Compliance & Security – Real-time AI monitoring detects risks and enforces data protection protocols to safeguard sensitive health information.
Webinar Details
-
Date: Thursday, August 21, 2025
-
Time:12:00 PM EST
-
Format:Webinar – https://www.vescell.health/events
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient’s own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.